본문 바로가기
KOR
ENG
KOR
ENG
about us
Dedicated to revolutionizing new drug discovery and development

History

More than 15 years of dedication to revolutionizing new drug therapies
2023
  • 06.
    IND approval of LCB84(Anti-TROP2 ADC) for phase 1/2
  • 12.
    LCB enters into Licensing agreement with Janssen for Trop2 ADC
2022
  • 01.
    Approval of LCB14 (HER2 ADC) phase 2 clinical trial in China
  • 04.
    LCB enters into In-licensing agreement with Harbour BioMed
  • 03.
    Established 'AntibodyChem Bioscienses', a subsidiary in Boston, USA
  • 09.
    LCB14 'World ADC summit' clinical phase 1 interim data released
  • 11.
    LCB and NextCure in the US Enter into Co-Development Agreement to Develop ADC
  • 11.
    Delpazolid, designated as an orphan drug by the EMA
  • 11.
    SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
  • 12.
    LCB and Amgen enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
2021
  • 05.
    LCB enters into In-licensing agreement with Mediterranea Theranostic for Trop-2 antibody
  • 06.
    LCB and Iksuda Enter Into a expansion of License Agreement for the Development of Antibody-Drug Conjugates
  • 10.
    Awarded 'Best ADC Platform Technology' for 4 consecutive years at'World ADC Awards 2021'
  • 11.
    LCB and Sotio Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
  • 12.
    LCB and IKSUDA enter Co-development & License Agreement for Antibody Drug Conjugate program (anti-HER2 ADC)
2020
2019
2018
  • 01.
    LCB enters into third party Licensing agreement with Lee's Pharm for LCB02-0133
  • 01.
    Delpazolid designated for Fast Track by US FDA
2017
  • 08.
    Japanese patent registration on the unique ADC platform technology ConjuALL
  • 07.
    Delpazolid designated for Orphan Drug by US FDA
  • 05.
    LCB enters into third party Licensing agreement with BridgeBio for BBT-877
  • 04.
    US patent registration on the unique ADC platform technology ConjuALL
  • 01.
    Patent acquisition on LegoChem Bio, ADC antibody structure and manufacturing method
  • 01.
    LCB enters into research licensing agreement with Takeda
2016
  • 12.
    LCB enters licensing agreement with RMX Biopharma for LCB01-0371 (gram-positive antibiotic) regarding China market.
  • 08.
    LCB Initiates clinical trial phase I of oxazolidinone antibiotic LCB01-0371 (IV)
  • 07.
    LCB sets up a Joint Venture for the global development of Cephalosporin antibiotic LCB10-0200
  • 06.
    LCB obtains patent for its novel linker chemistry (Compounds Comprising Self-immolative group)
  • 05.
    LCB initiates clinical trial phase II of oxazolidinone antibiotic LCB01-0371 (PO)
  • 05.
    Mechanical completion of API Plant I (LegoChem Pharma)
  • 08.
    LCB extends designation as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy
2015
  • 12.
    Acquisition of Khanmed & Hanbul Pharma
  • 11.
    LCB enters into a Joint Research agreement with Theranyx
  • 08.
    LCB licenses out anti-Her2 ADC to Fosun Pharma for the Greater Chinese market
2014
  • 10.
    LCB01-0371 (oxazolidinone antibiotic) is selected as a “PHARM NAVI” project by the MFDS (Ministry of Food and Drug Safety)
  • 09.
    Completion of clinical trial phase 1 for LCB02-0133 (FXa, Anti-Coagulant Candidate)
  • 08.
    LCB is designated as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy.
2013
  • 08.
    LCB Initiates pre-clinical trial of cephalosporin antibiotic LCB10-0200
  • 07.
    LCB’s ADC (Antibody Drug Conjugate) is selected as an investment related project by the Small and Medium Business Administration (SMBA).
  • 05.
    LCB (141080) is listed on KOSDAQ through Initial Public Offering
2012
  • 12.
    LCB enters into a collaboration agreement with AstraZeneca and license out its cephalosporion antibiotic candidate LCB10-0200
  • 12.
    LCB enters into a collaboration agreement with Green Cross to develop Next-generation Antibody-Drug Conjugates
  • 07.
    LCB enters into a collaboration agreement with Sanofi to develop novel oncologics
  • 06.
    LCB designated as an INNO-BIZ company
  • 03.
    CB named as “Emerging Company of the Year 2012” (BioSpectrum Aisa, Singapore)
  • 02.
    LCB initiates clinical trial phase I of FXa inhibitor anti-coagulant candidate LCB02-0133
2011
  • 11.
    US FDA IND approval for anti-coagulant candidate LCB02-0133
  • 07.
    LCB02-0133(Anit-coagulant, FXa inhibitor) selected as Global New Drug Discovery Project by Korean Ministry of Education, Science, and Technology
2010
  • 12.
    Completed non-clinical trials of an oxazolidinone antibiotic
  • 10.
    Signed a joint research contract on anticancer drugs with Interprotein in Japan (Project title: VEGF inhibitor)
  • 09.
    Presented research findings on antibiotics at 2010 ICAAC in Boston, United States
2009
  • 12.
    LCB presents antibiotic study result at the 2009 “ICAAC” San Francisco
  • 06.
    LCB successfully license-out its preclinical stage Anti-coagulant candidate LCB02-0133 (FXa inhibitor)
  • 01.
    Joint research contract with The Catholic Univ. School of Medicine (ophthalmic medicine: Wondonin) is executed
2008
  • 05.
    LCB receives Korean MOHW (Ministry of Health and Welfare) researching funding for oxazolidinone antibiotic candidate.
2007
  • 09.
    LCB presents oxazolidinone antibiotic study result at the Chicago “ICAAC” Conference 2007
2006
  • 05.
    LCB is founded
Privacy Policy · Products · Inquiry · Company Location
ⓒ LIGACHEM BIOSCIENCES Inc. ALL RIGHTS RESERVED.